EULAR 难治性类风湿关节炎定义
EULAR 工作组基于国际风湿病学家调查起草定义,经包括风湿病学家、护士、健康专业人员和患者的工作组面对面讨论修订至足够共识,提出难治性 RA 定义。定义包含三项强制要素:按 EULAR 推荐治疗且 csDMARD 失败后 ≥2 种不同机制 bDMARD/tsDMARD 失败;至少一项活动性疾病指标;医生和/或患者认为管理困难。
要点
- 难治性 RA 须满足三项强制标准,缺一不可。
- 标准一:按 EULAR 推荐治疗,csDMARD 失败后 ≥2 种不同机制 bDMARD/tsDMARD 失败(除非禁忌)。
- 标准二:至少一项活动性疾病指标,标准三:医生和/或患者认为管理困难。
核心结论
- EULAR 提出的难治性 RA 定义包含三项强制要素,可用于临床实践、临床试验并作为未来研究基础。
研究设计与样本
- 指导委员会基于国际风湿病学家调查起草定义,工作组(含风湿病学家、护士、健康专业人员和患者)面对面讨论修订至投票达到足够共识。
主要发现
- 所有工作组成员一致同意三项标准为难治性 RA 定义的强制要素。
关键数值与推荐
- 标准一:按 EULAR 推荐治疗,csDMARD 治疗失败后(除非禁忌)≥2 种不同作用机制的 bDMARD/tsDMARD 失败。
- 标准二:至少满足以下之一:至少中度疾病活动;提示活动性疾病的体征和/或症状;无法减少糖皮质激素治疗;快速影像学进展;RA 症状导致生活质量下降。
- 标准三:医生和/或患者认为体征和/或症状的管理存在问题。
临床怎么用
- 该定义可用于临床实践中识别难治性 RA 患者,也可用于临床试验和未来研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. OBJECTIVE: The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. METHODS: The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). RESULTS: The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ≥2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. CONCLUSIONS: The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
引用
- Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2020. PMID: 33004335. doi:10.1136/annrheumdis-2020-217344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。